We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
May 23, 2025
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.
May 15, 2025
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
Crinetics will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, taking place May 15–17 in Orlando, FL.
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for endocrine diseases and endocrine oncology such as:
- Acromegaly
- Carcinoid syndrome
- ACTH-dependent Cushing’s syndrome
- Congenital adrenal hyperplasia (CAH)
- Hyperparathyroidism
- Polycystic kidney disease
- Graves’ disease
- TED
- Diabetes
- Obesity
- Hyperinsulinism
Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Approved |
---|---|---|---|---|---|
Acromegaly
Congenital Adrenal Hyperplasia (CAH)
NETs and SST2-Expressing Tumors
Hyperparathyroidism
Graves' Disease, TED
Polycystic Kidney Disease
Hyperinsulinism
Diabetes, Obesity
Diabetes, Obesity
Targeted Radiotherapy for Multiple Solid-Tumors
Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Approved |
---|---|---|---|---|---|
Acromegaly
Congenital Adrenal Hyperplasia (CAH)
NETs and SST2-Expressing Tumors
Hyperparathyroidism
Polycystic Kidney Disease
Hyperinsulinism
Graves' Disease, TED
Diabetes, Obesity
Diabetes, Obesity
Targeted Radiotherapy for Multiple Solid-Tumors